A new study finds anifrolumab (Saphnelo) may reduce harmful inflammation and improve signs of overall immune health. These benefits could also help improve long-term health and quality of life for people with moderate-to-severe systemic lupus erythematosus (SLE).  

Researchers analyzed outcomes of 536 people with moderate-to-severe SLE participating in the phase 3 TULIP-1/2 trials and followed 369 of the 536 who also participated in the 3-year, long-term trial extension. Their lymphocytes, hemoglobin, platelets, neutrophils, complement C3, C4, anti–double-stranded DNA (dsDNA), and Igs were analyzed to week 208. Over time, more people treated with anifrolumab had their white blood cell and hemoglobin levels return to normal compared with those who received a placebo; platelet levels returned to normal at similar rates in both study groups. These improvements lasted through the four-year long-term study. The number of people who still had low white blood cell counts or anemia decreased in both groups, but overall, improvements in blood cell levels (including white blood cells, hemoglobin, and platelets) were greater and lasted longer in the anifrolumab group.  

These improved blood and immune test results show that anifrolumab works well long-term for people with moderate-to-severe SLE.  Additionally, the link between clinical improvement and better biomarkers suggests the treatment helps restore overall immune health. Continue to follow the Lupus Foundation of America for updates on lupus treatments and talk to your doctor before making any changes to your treatment. Learn more about Saphnelo. 

Read the study